Ngā hua rapu - Xingxing Zang

Whakamahine hua
  1. 1
    2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade – A personal account

    2018 Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade – A personal account mā Xingxing Zang

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Serine proteinase inhibitors from nematodes and the arms race between host and pathogen

    Serine proteinase inhibitors from nematodes and the arms race between host and pathogen mā Xingxing Zang, Rick M. Maizels

    I whakaputaina 2001
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    The PD‐1/PD‐L1 (B7‐H1) Pathway in Chronic Infection‐Induced Cytotoxic T Lymphocyte Exhaustion

    The PD‐1/PD‐L1 (B7‐H1) Pathway in Chronic Infection‐Induced Cytotoxic T Lymphocyte Exhaustion mā Kimberly A. Hofmeyer, Hyungjun Jeon, Xingxing Zang

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    The contrasting role of B7-H3

    The contrasting role of B7-H3 mā Kimberly A. Hofmeyer, Anjana Ray, Xingxing Zang

    I whakaputaina 2008
    Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

    Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy mā Élodie Picarda, Kim C. Ohaegbulam, Xingxing Zang

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance

    Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance mā Phillip M. Galbo, Xingxing Zang, Deyou Zheng

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1

    Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1 mā Amer Assal, Justin D. Kaner, Gopichand Pendurti, Xingxing Zang

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity

    Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity mā Joyce Wei, P’ng Loke, Xingxing Zang, James P. Allison

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Immune Checkpoint Blockade in Human Cancer Therapy: Lung Cancer and Hematologic Malignancies

    Immune Checkpoint Blockade in Human Cancer Therapy: Lung Cancer and Hematologic Malignancies mā Murali Janakiram, Vipul Pareek, Haiying Cheng, Deepa Maheswari Narasimhulu, Xingxing Zang

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies

    PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies mā Christopher Nishimura, Marc C. Pulanco, Wei Cui, Liming Lu, Xingxing Zang

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

    HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families mā Murali Janakiram, Jordan M. Chinai, Aimin Zhao, Joseph A. Sparano, Xingxing Zang

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

    Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway mā Kim C. Ohaegbulam, Amer Assal, Eszter Lázár‐Molnár, Yu Yao, Xingxing Zang

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

    Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies mā Hao Wang, Gurbakhash Kaur, Alexander Sankin, Fuxiang Chen, Fangxia Guan, Xingxing Zang

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial

    The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial mā Peter John, Wei Yao, Weifeng Liu, Meirong Du, Fangxia Guan, Xingxing Zang

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Macrophage plasticity and function in cancer and pregnancy

    Macrophage plasticity and function in cancer and pregnancy mā Tingxuan Yin, Xinyi Li, Yanhong Li, Xingxing Zang, Lu Liu, Meirong Du

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    New immunotherapies targeting the PD-1 pathway

    New immunotherapies targeting the PD-1 pathway mā Jordan M. Chinai, Murali Janakiram, Fuxiang Chen, Wantao Chen, Mark Kaplan, Xingxing Zang

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Immune evasion genes from filarial nematodes

    Immune evasion genes from filarial nematodes mā Rick M. Maizels, Natalia Gomez‐Escobar, William F. Gregory, Janice Murray, Xingxing Zang

    I whakaputaina 2001
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    The third group of the B7‐<scp>CD</scp>28 immune checkpoint family: <scp>HHLA</scp>2, <scp>TMIGD</scp>2, B7x, and B7‐H3

    The third group of the B7‐<scp>CD</scp>28 immune checkpoint family: <scp>HHLA</scp>2, <scp>TMIGD</scp>2, B7x, and B7‐H3 mā Murali Janakiram, Urvi A. Shah, Weifeng Liu, Aimin Zhao, Mark Schoenberg, Xingxing Zang

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    B7x: A widely expressed B7 family member that inhibits T cell activation

    B7x: A widely expressed B7 family member that inhibits T cell activation mā Xingxing Zang, P’ng Loke, Jayon Kim, Kenneth M. Murphy, Rebecca Waitz, James P. Allison

    I whakaputaina 2003
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    A<i>Brugia malayi</i>Homolog of Macrophage Migration Inhibitory Factor Reveals an Important Link Between Macrophages and Eosinophil Recruitment During Nematode Infection

    A<i>Brugia malayi</i>Homolog of Macrophage Migration Inhibitory Factor Reveals an Important Link Between Macrophages and Eosinophil Recruitment During Nematode Infection mā Franco H. Falcone, P’ng Loke, Xingxing Zang, Andrew S. MacDonald, Rick M. Maizels, Judith E. Allen

    I whakaputaina 2001
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: